https://scholars.lib.ntu.edu.tw/handle/123456789/468864
標題: | Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas | 作者: | SUNG-HSIN KUO KUN-HUEI YEH MING-SHIANG WU CHUNG-WU LIN PING-NING HSU HSIU-PO WANG Chen L.-T. ANN-LII CHENG |
公開日期: | 2012 | 卷: | 119 | 期: | 21 | 起(迄)頁: | 4838-4844 | 來源出版物: | Blood | 摘要: | An explorative study evaluates the efficacy of Helicobacter pylori (HP) eradication (HPE) therapy on early-stage gastric diffuse large B-cell lymphomas (DLBCLs) without features of mucosa-associated lymphoid tissue (MALT), the pure (de novo) DLBCLs, in comparison with its efficacy on high-grade transformed gastric MALT lymphomas, the DLBCL(MALT). In total, 50 patients of stage IE/IIE1 HP-positive gastric DLBCLs with frontline HPE treatment were included. HP infection was successfully eradicated in 100% (16/16) of the pure (de novo) DLBCL patients and 94.1% (32/34) of the DLBCL(MALT) patients. In total, 68.8% (11/16) of pure (de novo) DLBCL patients and 56.3% (18/32) of DLBCL(MALT) patients achieved complete pathologic remission (pCR) after HPE therapy. The median time to pCR was 2.1 months (95% confidence interval, 0.6%-3.7%) for pure (de novo) DLBCLs and 5.0 months (95% confidence interval, 2.8%-7.5%; P ? .024) for DLBCL(MALT). At a median follow-up of 7.7 years, all patients with pCR after HPE therapy were alive and free of lymphomas, except for one patient with pure (de novo) DLBCL who died of lung cancer. Similar to DLBCL(MALT), a substantial portion of early-stage HP-positive gastric pure (de novo) DLBCLs remains HP-dependent and responds to antibiotic treatment. Prospective studies to validate the findings are warranted. ? 2012 by The American Society of Hematology. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84861515828&doi=10.1182%2fblood-2012-01-404194&partnerID=40&md5=fc91e9f94bf9f503353d7f4e5d923687 https://scholars.lib.ntu.edu.tw/handle/123456789/468864 |
ISSN: | 0006-4971 | DOI: | 10.1182/blood-2012-01-404194 | SDG/關鍵字: | amoxicillin; antineoplastic agent; bismuth citrate; clarithromycin; metronidazole; omeprazole; adult; aged; antibiotic therapy; article; cancer grading; cancer regression; cancer staging; cancer survival; cause of death; controlled clinical trial; controlled study; drug efficacy; female; follow up; gastroscopy; Helicobacter infection; human; human tissue; large cell lymphoma; lung non small cell cancer; major clinical study; male; mucosa associated lymphoid tissue lymphoma; multicenter study; overall survival; priority journal; stomach lymphoma; treatment outcome; treatment response |
顯示於: | 病理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。